Treat your mHSPC patients early with ERLEADA® + ADT
At 44 months of median follow-up, the TITAN final analysis confirms a range of benefits for a broad population of patients with mHSPC.[2][3]
With ERLEADA® + ADT, you can delay disease progression and extend the life of your mHSPC patients.[2][3]
- 65.1% OS rate with ERLEADA® + ADT vs. 51.8% with placebo + ADT at 48 months[2]a
- 52% reduction in the risk of rPFS vs. placebo + ADT at 2 years; HR: 0.48 (95% CI: 0.39–0.60) p<0.001[3]
You can offer this range of benefits to your mHSPC patients with ERLEADA® + ADT, whilst providing a consistent, acceptable safety profile that is comparable to placebo + ADT.[2][3]
aThe majority of patients were still alive at time of final analysis.[3]
Why treat early with ERLEADA® + ADT?
Treat early to prolong survival and delay progression vs. placebo + ADT[2]
Treat early with ERLEADA® + ADT and provide an additional treatment option for mHSPC patients[2]
Treat early in a broad range of mHSPC patients[2]
Treat early and help maintain QoL[2]
Abbreviations
ADT, androgen deprivation therapy. CI, confidence interval. HR, hazard ratio. mHSPC, metastatic hormone-sensitive prostate cancer. OS, overall survival. QoL, quality of life. rPFS, radiographic progression-free survival.
▼ Este medicamento está sujeito a monitorização adicional. Titular da Autorização de Introdução no Mercado: Janssen-Cilag International NV, Turnhoutseweg 30, B-2340 Beerse, Bélgica.
Para mais informações deverá contactar o Representante do Titular da Autorização de Introdução no Mercado: Janssen-Cilag Farmacêutica, Lda.
Medicamento de receita médica restrita, de utilização reservada a certos meios especializados.
Antes de prescrever consulte o RCM completo.
RCM de Erleada®, veja aqui
